Medtrum Technologies Inc.
Simplifying Diabetes
Simplifying Diabetes
Medtrum Technologies Inc. is a biotechnology and health care startup based in China, founded in 2008. With the slogan "Simplifying Diabetes," the company offers innovative solutions for diabetes management, including tubeless insulin pumps, continuous glucose monitoring systems, and a semi-closed loop system containing both pump and CGM. These products are designed for both home and clinic use, aiming to bring convenience to patients and healthcare providers. The company's recent achievement includes a $29.06M Series C investment on 25th December 2018. The investment was led by 3E Bioventures Capital, Bank of China Group Investment Limited, Sequoia Capital China, ZJ Innopark (Zhangjiang Hi-Tech Park), and Shanghai Nuokai Investment Management. Medtrum Technologies' mission is to develop a closed-loop artificial pancreas, furthering their goal to simplify diabetes management. The company's focus on addressing a critical health issue and its strategic partnerships make it an attractive prospect for potential investors in the health and biotechnology sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $29.06M | 5 |
|
25 Dec 2018 |
| Series B | Unknown | - | 09 Jan 2018 |
No recent news or press coverage available for Medtrum Technologies Inc..
We care about your data, and we'd love to use cookies make your experience better.
